The Journal of Thoracic and Cardiovascular Surgery, Vol 71, 161-168, Copyright © 1976 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
Immunologic defects in lung cancer patients
EC Holmes and SH Golub
Ninety-three patients with lung cancer were evaluated by delayed cutaneous
hypersensitivity testing. Twenty-eight of these patients were evaluated by
in vitro lymphocyte function. Thirty-three patients were evaluated prior to
surgery and defects in the immune response were closely associated with
unresectable disease. In vitro and in vivo studies indicate an antigen
recognition defect in the cellular immune mechanisms of these patients.
Preliminary studies suggest that the immunopotentiating agent Levamisole
may be able to augment this defective cellular immunity in patients with
lung cancer.